CN101068564B - 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 - Google Patents

含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 Download PDF

Info

Publication number
CN101068564B
CN101068564B CN2005800416406A CN200580041640A CN101068564B CN 101068564 B CN101068564 B CN 101068564B CN 2005800416406 A CN2005800416406 A CN 2005800416406A CN 200580041640 A CN200580041640 A CN 200580041640A CN 101068564 B CN101068564 B CN 101068564B
Authority
CN
China
Prior art keywords
compositions
vegf
trap
treatment
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800416406A
Other languages
English (en)
Chinese (zh)
Other versions
CN101068564A (zh
Inventor
P·弗里格诺德
M·奇龙-布隆德尔
M·-C·比塞里
E·弗菲恩
J·霍拉什
J·M·塞达鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Co ltd
Sanofi Metso Intellectual Property
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101068564(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN101068564A publication Critical patent/CN101068564A/zh
Application granted granted Critical
Publication of CN101068564B publication Critical patent/CN101068564B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800416406A 2004-12-03 2005-12-02 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 Expired - Lifetime CN101068564B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
FR0412870 2004-12-03
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (2)

Publication Number Publication Date
CN101068564A CN101068564A (zh) 2007-11-07
CN101068564B true CN101068564B (zh) 2010-12-15

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800416406A Expired - Lifetime CN101068564B (zh) 2004-12-03 2005-12-02 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物

Country Status (25)

Country Link
US (3) US20060178305A1 (https=)
EP (1) EP1824504B1 (https=)
JP (1) JP4980236B2 (https=)
KR (1) KR101313404B1 (https=)
CN (1) CN101068564B (https=)
AT (1) ATE426409T1 (https=)
AU (1) AU2005311191C1 (https=)
BR (1) BRPI0518700B8 (https=)
CA (1) CA2586735C (https=)
CY (3) CY1109181T1 (https=)
DE (1) DE602005013568D1 (https=)
DK (1) DK1824504T3 (https=)
ES (1) ES2324233T3 (https=)
FR (3) FR2878749B1 (https=)
HR (1) HRP20090336T1 (https=)
IL (1) IL183481A (https=)
LU (2) LU92202I2 (https=)
ME (1) ME01706B (https=)
MX (1) MX2007006607A (https=)
PL (1) PL1824504T3 (https=)
PT (1) PT1824504E (https=)
RS (1) RS50769B (https=)
RU (1) RU2384344C2 (https=)
SI (1) SI1824504T1 (https=)
WO (1) WO2006059012A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN100523187C (zh) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ada H. Braun et al.New systemic frontline treatment for metastaticcolorectalcarcinoma.CANCER100 8.2004,100(8),1558-1577.
Ada H. Braun et al.New systemic frontline treatment for metastaticcolorectalcarcinoma.CANCER100 8.2004,100(8),1558-1577. *
HURWITZ H et al.Bevacizumab plus Irinotecan,Fluorouracil, and LeucovorinforMetastatic Colorectal Cancer.NEW ENGLAND JOURNAL OF MEDICINE350 23.2004,350(23),2335-2342.
HURWITZ H et al.Bevacizumab plus Irinotecan,Fluorouracil, and LeucovorinforMetastatic Colorectal Cancer.NEW ENGLAND JOURNAL OF MEDICINE350 23.2004,350(23),2335-2342. *
李军等.VEGF 肿瘤血管再生及抗肿瘤血管生成治疗.医师进修杂志（外科版）27 4.2004
李军等.VEGF,肿瘤血管再生及抗肿瘤血管生成治疗.医师进修杂志(外科版)27 4.2004,27(4),52-54. *

Also Published As

Publication number Publication date
MX2007006607A (es) 2007-07-25
ME01706B (me) 2010-08-31
BRPI0518700B1 (pt) 2020-02-11
AU2005311191A1 (en) 2006-06-08
WO2006059012A1 (fr) 2006-06-08
EP1824504A1 (fr) 2007-08-29
FR13C0024I1 (fr) 2013-05-24
PT1824504E (pt) 2009-06-25
DE602005013568D1 (de) 2009-05-07
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
BRPI0518700B8 (pt) 2021-05-25
EP1824504B1 (fr) 2009-03-25
KR101313404B1 (ko) 2013-10-01
IL183481A0 (en) 2007-09-20
HRP20090336T1 (hr) 2009-07-31
CA2586735A1 (fr) 2006-06-08
AU2005311191B2 (en) 2011-12-08
FR13C0025I1 (fr) 2013-05-24
LU92203I2 (fr) 2013-11-15
US8388963B2 (en) 2013-03-05
FR2878749A1 (fr) 2006-06-09
LU92202I9 (https=) 2019-01-15
DK1824504T3 (da) 2009-07-20
LU92202I2 (fr) 2013-11-15
IL183481A (en) 2013-09-30
HK1114769A1 (en) 2008-11-14
FR2878749B1 (fr) 2007-12-21
CA2586735C (fr) 2014-08-12
RU2007123607A (ru) 2009-01-10
ES2324233T3 (es) 2009-08-03
US20060178305A1 (en) 2006-08-10
CY2013018I1 (el) 2020-05-29
ATE426409T1 (de) 2009-04-15
CN101068564A (zh) 2007-11-07
RU2384344C2 (ru) 2010-03-20
BRPI0518700A2 (pt) 2008-12-02
JP2008521866A (ja) 2008-06-26
JP4980236B2 (ja) 2012-07-18
PL1824504T3 (pl) 2009-08-31
CY2013017I1 (el) 2014-07-02
RS50769B (sr) 2010-08-31
CY1109181T1 (el) 2014-07-02
KR20070091130A (ko) 2007-09-07
AU2005311191C1 (en) 2015-04-30
SI1824504T1 (sl) 2009-08-31
LU92203I9 (https=) 2019-01-15

Similar Documents

Publication Publication Date Title
AU2008290442B2 (en) Antitumour combinations containing a VEGF inhibiting agent and Irinotecan
US8388963B2 (en) Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
US20170232017A1 (en) Treatment of cancer
US6979682B2 (en) Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
EP3570849B1 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
HK1114769B (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
HK1141241A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
HK1194298A (en) Antitumour combinations containing a vegf inhibiting agent and irinotecan
HK1128234B (en) Combination comprising combretastatin and anticancer agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114769

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1114769

Country of ref document: HK

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: French Gentilly

Patentee after: Aventis Pharmaceuticals Co.,Ltd.

Address before: French Anthony

Patentee before: AVENTIS PHARMA S.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231129

Address after: French Gentilly

Patentee after: Sanofi Metso Intellectual Property

Address before: French Gentilly

Patentee before: Aventis Pharmaceuticals Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20101215

CX01 Expiry of patent term